Pharma Mar Sustainability Profile
Pharma Mar, officially known as Pharma Mar S.A., is a leading biopharmaceutical company headquartered in Madrid, Spain. Founded in 1986, the company has established itself as a pioneer in the research and development of marine-derived medicines, particularly in the oncology sector. With a strong focus on innovative therapies, Pharma Mar has made significant strides in the treatment of cancer, leveraging unique compounds sourced from the ocean. The company’s flagship products, including Yondelis and Aplidin, are distinguished by their novel mechanisms of action and have garnered attention in both clinical and commercial arenas. Pharma Mar's commitment to advancing cancer treatment has positioned it as a key player in the global biopharmaceutical landscape, with a robust pipeline and strategic partnerships enhancing its market presence.
DitchCarbon Score
How does Pharma Mar's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Pharma Mar's score of 83 is higher than 89% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Pharma Mar's reported carbon emissions
In 2024, Pharma Mar reported total carbon emissions of approximately 17,719,000 kg CO2e, with Scope 1 emissions at about 1,340,000 kg CO2e, Scope 2 emissions at approximately 247,000 kg CO2e, and a significant contribution from Scope 3 emissions, which totalled around 16,132,000 kg CO2e. The company has set ambitious climate commitments, aiming to reduce its Scope 1 and 2 emissions by 42% by 2030, based on a 2021 baseline. Furthermore, Pharma Mar has committed to an overall reduction of 90% in Scope 1, 2, and 3 emissions by 2050, also from a 2021 base year. These targets align with the Science Based Targets initiative (SBTi) and are designed to support the global goal of limiting temperature rise to 1.5°C. Pharma Mar's emissions data is sourced directly from its own reporting, with no cascaded data from parent organizations. The company is actively working towards these targets, reflecting its commitment to sustainability within the pharmaceutical sector.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|
| Scope 1 | 1,373,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 1,237,000 | 0,000,000 | 000,000 | 000,000 |
| Scope 3 | 12,449,000 | 00,000,000 | 00,000,000 | 00,000,000 |
How Carbon Intensive is Pharma Mar's Industry?
How Carbon Intensive is Pharma Mar's Location?
Pharma Mar's Scope 3 Categories Breakdown
Pharma Mar's Scope 3 emissions, which increased by 2% last year and increased by approximately 30% since 2021, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Capital Goods" being the largest emissions source at 49% of Scope 3 emissions.
Top Scope 3 Categories
Pharma Mar's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Pharma Mar has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Frequently Asked Questions
Common questions about Pharma Mar's sustainability data and climate commitments